King Pharmaceuticals Inc.: PharmaVitae Profile

Table of Contents

ABOUT THIS PROFILE

• PharmaVitae Explorer database
• Chapter structure
  • Quarterly news update
  • Company introduction
  • Company sales
  • Company financials
  • Key products and competitors

• Data sourcing
  • Analyst consensus

EXECUTIVE SUMMARY

• Key findings
• Prescription pharmaceutical sales and growth rate performance, 2002-14
• Financial performance, 2002-14
• King Pharmaceuticals: PharmaVitae forecasts at a glance
• Strategic insight
  • Alpharma acquisition has significantly improved King' s outlook
  • King-Alpharma combination creates a key player in the pain market

• SWOT analysis
  • Strengths
  • Weaknesses
  • Opportunities
  • Threats

QUARTERLY NEWS UPDATE

• Quarterly sales update, Q2 2009
• Product developments
• Deals and alliances
• M&A activity
• Company announcements
• Future product milestones

COMPANY INTRODUCTION

• Key findings
• Background
• Key corporate developments
• M&A history
  • Elan deal creates life after Altace
  • Mylan acquisition failed to materialize
  • Alpharma acquisition completed in December 2008

• Current corporate structure
• Pharmaceuticals business unit structure

COMPANY SALES

• Key findings
• Prescription pharmaceutical sales and growth rate analysis, 2002-14
• Product analysis
  • Product analysis, 2002-08
  • Product analysis, 2008-14

• Therapy area analysis
• Geographic analysis
• Launch/core/expiry analysis
  • Explanation of launch/core/expiry analysis
  • Launch analysis, 2008-14
  • Core analysis, 2008-14
  • Expiry analysis, 2008-14
  • Launch/core/expiry configuration, 2008-14

• Molecule type analysis
• Externalization analysis

COMPANY FINANCIALS

• Key findings
• Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08
• Operating costs and profit analysis
• Operating costs and profit analysis, 2002-08
  • Operating cost ratio and profit margin analysis, 2002-08
  • Operating cost ratio and profit margin analysis, 2008-14
  • Operating costs and profit analysis, 2008-14

KEY PRODUCTS AND COMPETITORS

• Key findings
• Overview
• Central nervous system
  • Remoxy
  • Flector
  • Acurox
  • Embeda
  • Avinza

• Immunology and inflammation
  • EpiPen

• Hematology
  • Thrombin-JMI

• Cardiovascular
  • Altace

APPENDIX

• R&D pipeline
• References
• Abbreviations
• Exchange rates

TABLES

• Table: King - PharmaVitae forecasts at a glance
• Table: King key product developments, 2009
• Table: King product deals and alliances, 2009
• Table: King M&A activity, 2009
• Table: King company announcements, 2009
• Table: King future product milestones, 2009-11
• Table: King product portfolio overview ($m), 2002-08
• Table: King product portfolio overview ($m), 2008-14
• Table: King prescription pharmaceutical sales by therapy area ($m), 2008-14
• Table: King prescription pharmaceutical sales by geographic region ($m), 2008-14
• Table: King launch portfolio overview ($m), 2008-14
• Table: King core portfolio overview ($m), 2008-14
• Table: King expiry portfolio overview ($m), 2008-14
• Table: King prescription pharmaceutical sales by molecule type ($m), 2008-14
• Table: King prescription pharmaceutical sales by source ($m), 2008-14
• Table: Total King sales by business unit ($m), 2002-08
• Table: King operating revenue/cost analysis ($m), 2002-08
• Table: King operating cost ratio analysis (% of total revenues), 2002-08
• Table: King operating cost ratio analysis (% of total revenues), 2008-14
• Table: King operating revenue/cost analysis ($m), 2008-14
• Table: Key products overview
• Table: Remoxy: overview
• Table: Remoxy: sales forecast ($m), 2008-14
• Table: Flector: overview
• Table: Flector: sales forecast ($m), 2008-14
• Table: Acurox: overview
• Table: Acurox: sales forecast ($m), 2008-14
• Table: Embeda: overview
• Table: Embeda: sales forecast ($m), 2008-14
• Table: Avinza: overview
• Table: Avinza: sales forecast ($m), 2008-14
• Table: EpiPen: overview
• Table: EpiPen: sales forecast ($m), 2008-14
• Table: Thrombin-JMI: overview
• Table: Thrombin-JMI: sales forecast ($m), 2008-14
• Table: Altace: overview
• Table: Altace: sales forecast ($m), 2008-14
• Table: King' s R&D pipeline (Phase I-registration)
• Table: Exchange rates, 2009

FIGURES

• Figure: The PharmaVitae Explorer
• Figure: King prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14
• Figure: King' s financial performance ($m), 2002-14
• Figure: King major growth drivers/resistors, 2002-14
• Figure: King prescription pharmaceutical revenue by source company, 2002-14
• Figure: King launch, core and expiry configuration, 2008-14
• Figure: US analgesics market by company, percentage share (%), 2008-14
• Figure: King SWOT analysis
• Figure: Current corporate structure
• Figure: Pharmaceuticals business unit structure
• Figure: King prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14
• Figure: Key product sales ($m), 2002-14
• Figure: King key sales growth drivers and resistors ($m), 2002-08
• Figure: King key sales growth drivers and resistors ($m), 2008-14
• Figure: King prescription pharmaceutical sales by therapy area ($m), 2002-14
• Figure: King prescription pharmaceutical sales by geographic region ($m), 2002-14
• Figure: King launch/core/expiry configuration ($m), 2008-14
• Figure: King prescription pharmaceutical sales by molecule type ($m), 2002-14
• Figure: King prescription pharmaceutical sales by source ($m), 2002-14
• Figure: King operating revenue/cost analysis ($m), 2002-14